Placebos Fight Depression As Well As Drugs
- NHNE News List
Current Members: 732
Subscribe/unsubscribe/archive info at the bottom of this message.
Money needed = $916.00
Donations to date = $395.00
Number of people who have helped = 5
Funds still needed = $521.00
To make a tax-deductible donation:
Phone: (928) 282-6120
Fax: (815) 346-1492
Mail: NHNE, P.O. Box 2242, Sedona, AZ 86339
Credit Cards: Please include number, expiration date, phone number.
AGAINST DEPRESSION, A SUGAR PILL IS HARD TO BEAT
By Shankar Vedantam
Tuesday, May 7, 2002; Page A01
After thousands of studies, hundreds of millions of prescriptions and tens
of billions of dollars in sales, two things are certain about pills that
treat depression: Antidepressants like Prozac, Paxil and Zoloft work. And so
do sugar pills.
A new analysis has found that in the majority of trials conducted by drug
companies in recent decades, sugar pills have done as well as -- or better
than -- antidepressants. Companies have had to conduct numerous trials to
get two that show a positive result, which is the Food and Drug
Administration's minimum for approval.
What's more, the sugar pills, or placebos, cause profound changes in the
same areas of the brain affected by the medicines, according to research
published last week. One researcher has ruefully concluded that a higher
percentage of depressed patients get better on placebos today than 20 years
Placebos -- or dud pills -- have long been used to help scientists separate
the "real" effectiveness of medicines from the "illusory" feelings of
patients. The placebo effect -- the phenomenon of patients feeling better
after they've been treated with dud pills -- is seen throughout the field of
medicine. But new research suggests that the placebo may play an
extraordinary role in the treatment of depression -- where how people feel
spells the difference between sickness and health.
The new research may shed light on findings such as those from a trial last
month that compared the herbal remedy St. John's wort against Zoloft. St.
John's wort fully cured 24 percent of the depressed people who received it,
and Zoloft cured 25 percent -- but the placebo fully cured 32 percent.
The confounding and controversial findings do not mean that antidepressants
do not work. But clinicians and researchers say the results do suggest that
Americans may be overestimating the power of the drugs, and that the
medicines' greatest benefits may come from the care and concern shown to
patients during a clinical trial -- a context that does not exist for
millions of patients using the drugs in the real world.
"The drugs work, and I prescribe them, but they are not what they are
cracked up to be," said Wayne Blackmon, a Washington psychiatrist whose
practice largely comprises patients who suffer from depression. "I know from
clinical experience the drugs alone don't do the job."
Still, drugs may have become the reflexive treatment for the vast majority
of Americans receiving medical attention for depression: As the number of
doctor visits for depression rose from 14 million in 1987 to almost 25
million last year, medications were prescribed for nine in 10 patients,
according to research published last week.
It is not clear how many patients received medicines in a context of
therapy, although research has indicated that combining medicines with
psychotherapy produces the best results.
But Randall Stafford, the Stanford University physician who conducted the
study on doctor visits, found that less than one-third of them in 2001 were
to psychiatrists and two-thirds of them were to primary care physicians. The
former are more likely to situate the medicines in a larger context of
therapy, while the latter are less knowledgeable about therapy, more pressed
for time and less likely to offer patients anything like the attention they
would receive in a clinical trial.
The average participant in an eight-week trial spends about 20 hours being
examined by top experts and highly trained caregivers, said Seattle
psychiatrist Arif Khan, who studied the placebo effect in trials submitted
to the FDA. Participants -- including those being given sugar pills -- are
asked detailed questions about how they are feeling, and their every
psychological change is closely noted.
In comparison, Khan noted, the average patient with depression sees a doctor
perhaps 20 minutes a month.
His analysis of 96 antidepressant trials between 1979 and 1996 showed that
in 52 percent of them, the effect of the antidepressant could not be
distinguished from that of the placebo. Khan said the makers of Prozac had
to run five trials to obtain two that were positive, and the makers of Paxil
and Zoloft had to run even more. He analyzed trials that were made public in
the medical literature, which tend to show positive results, and those that
"It speaks to the difficulty we have in classifying and identifying the
disorders we deal with," said Thomas Laughren, who heads the group of
scientists at the FDA that evaluates the medicines. "Psychiatric diagnosis
is descriptive. We don't really understand psychiatric disorders at a
Patients with similar symptoms, he explained, may have different problems
with their brain chemistry. Scientists don't understand the neural
mechanisms of depression -- or why medicines like Prozac and Paxil work.
"We like to think we give people treatments and they get better," said
Andrew Leuchter, a professor of psychiatry at UCLA. "We have this fallacy of
success, but we don't know in any individual why they get better.
Undoubtedly one of those factors is the time we spend with people and the
connectedness that gives patients."
In January, Leuchter published a study in the American Journal of
Psychiatry, in which he tracked some of the brain changes associated with
drugs such as Prozac and Effexor, which are called selective serotonin
reuptake inhibitors. When Leuchter compared the brain changes in patients on
placebos, he was amazed to find that many of them had changes in the same
parts of the brain that are thought to control important facets of mood.
Patients who got better on placebos showed heightened activity in the
prefrontal lobe, and that activity continued to rise during the eight weeks
of the study. Those who responded to medicine initially showed a decline in
prefrontal brain activity, then a rise that eventually tapered off.
Thirty-eight percent of patients responded to the placebo, and 52 percent to
Once the trial was over and the patients who had been given placebos were
told as much, they quickly deteriorated. People's belief in the power of
antidepressants may explain why they do well on placebos. Patients in trials
are not told which they are receiving.
Likewise, sea changes in the treatment of depression -- including the
reduction in the stigma attached to mental illness, the widespread use of
antidepressants and the immense marketing efforts by their manufacturers --
may explain why Timothy Walsh, a psychiatrist at Columbia University,
recently found that the placebo effect has grown in recent years. He found
that greater percentages of people tended to get better on placebos during
trials of antidepressants in 2000 than in 1981.
Some observers assert that the medicines themselves work because of the
placebo effect, but most psychiatrists believe the drugs do have an effect
of their own. Drugs are a "placebo-plus" treatment, said Helen Mayberg, head
of neuropsychiatry at the Rotman Research Institute at the University of
In a study published last week in the American Journal of Psychiatry,
Mayberg evaluated brain changes during trials using a sophisticated brain
imaging technique. She found that medicines, besides working on areas that
are activated by placebos, also work on areas deep in the brain stem, the
hippocampus and striatum.
Since both depression and the effect of the medicines are still not well
understood, it's not clear what these changes mean. While they could be
irrelevant effects, Mayberg said a better explanation is that the drugs
affect areas deep within the brain and then work upward to affect parts of
the brain that control mood. Placebos may work in the reverse direction. In
part, this may explain why drug effects tend to be more reliable than
placebos in the long run.
Mayberg likened depression to a room with a hole in one window.
"You are trying to set a thermostat -- it's 100 degrees outside and you want
it to be 70," she said. "If you set the thermostat to 70, that doesn't work.
But if I set my thermostat to 50, that fools the system and gets the
temperature back to 70."
Both drugs and placebos -- chemicals and beliefs -- may impose different
chemical pressures on the brain that reset the "temperature." The real
problem, of course, is that no one knows how to fix the hole in the window,
or even where exactly it is. "This is a thousand-piece puzzle with no
picture on the box," sighed Mayberg.
Blackmon, the Washington psychiatrist, said it behooved mental health
clinicians to better integrate the power of biological treatments with the
effects of belief and therapy.
"We would say it's absurd if an internist says, 'I believe in penicillin, so
everyone should get penicillin whether they have cancer or a broken bone,"
RELATED NHNE NEWS LIST ARTICLES:
THE NOCEBO EFFECT: PLACEBO'S EVIL TWIN (5/2/2002):
THE PLACEBO EFFECT: THE POWER OF NOTHING (5/26/2001):
NHNE News List:
To subscribe, send a message to:
To unsubscribe, send a message to:
To review current posts:
Published by NewHeavenNewEarth (NHNE)
NHNE Website: http://www.nhne.com/
Phone: (928) 282-6120
Fax: (815) 346-1492
Appreciate what we are doing?
You can say so with a tax-deductible donation:
P.O. Box 2242
Sedona, AZ 86339